Zacks Investment Research cut shares of Chromadex Corp (OTCMKTS:CDXC) from a hold rating to a sell rating in a research report released on Monday.
According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. “
Other equities research analysts also recently issued reports about the company. ValuEngine upgraded Chromadex Corp from a sell rating to a hold rating in a research report on Tuesday, June 20th. HC Wainwright set a $6.00 target price on Chromadex Corp and gave the stock a buy rating in a research report on Monday, March 20th.
Shares of Chromadex Corp (OTCMKTS CDXC) opened at 3.62 on Monday. The company’s 50-day moving average price is $3.58 and its 200-day moving average price is $3.06. The stock’s market cap is $144.04 million. Chromadex Corp has a one year low of $2.25 and a one year high of $4.55.
WARNING: “Chromadex Corp (OTCMKTS:CDXC) Downgraded by Zacks Investment Research” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/07/20/chromadex-corp-otcmktscdxc-downgraded-by-zacks-investment-research.html.
In other news, major shareholder Step Holdings Ltd Pioneer bought 2,521,526 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The shares were bought at an average cost of $2.60 per share, for a total transaction of $6,555,967.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Large investors have recently modified their holdings of the company. Tieton Capital Management LLC bought a new stake in shares of Chromadex Corp during the first quarter valued at $1,853,000. Segall Bryant & Hamill LLC boosted its stake in shares of Chromadex Corp by 0.3% in the first quarter. Segall Bryant & Hamill LLC now owns 38,834 shares of the company’s stock valued at $104,000 after buying an additional 133 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Chromadex Corp during the second quarter valued at $168,000. Finally, North Star Investment Management Corp. boosted its stake in shares of Chromadex Corp by 78.9% in the second quarter. North Star Investment Management Corp. now owns 265,334 shares of the company’s stock valued at $1,014,000 after buying an additional 117,000 shares during the last quarter.
About Chromadex Corp
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Get a free copy of the Zacks research report on Chromadex Corp (CDXC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with MarketBeat.com's FREE daily email newsletter.
